Fred D. Ledley, MD, is Director of the Center for Integration of Science and Industry at Bentley University, a Professor in the Department of Natural & Applied Sciences and Department of Management and a Member of Bentley’s Health Thought Leadership Network. A recognized opinion leader in the integration of basic science with medicine, business, society and education, he is the author of >200 published works in fields ranging from biotechnology business and finance to molecular human biology, drug development, bioethics and STEM education. Ledley has served on the faculties of the Howard Hughes Medical Institute and the Baylor College of Medicine, and was involved in founding biotechnology companies including GeneMedicine (IPO NASDAQ:GMED), serving as Vice President, R&D, and Variagenics (IPO NASDAQ:VGEN), serving as President & CEO. He has served on the Board of Directors of MassBIO, the Board of Overseers of Boston Children’s Hospital and as a consultant to industry, academia and government. He has a BS from the University of Maryland, an MD from Georgetown University, trained in Pediatrics at Boston Children’s Hospital and was an American Cancer Society fellow with Dr. David Baltimore at MIT.
Matthew J. Jackson, PhD, is a Research Fellow at the Center for Integration of Science and Industry at Bentley University. He received a BSc in Pharmacology from the University of Dundee and an MSc in Stratified Medicine and Pharmacological Innovation from the University of Glasgow. He gained his PhD in Cellular Medicine from Newcastle University, UK, investigating effects of oxidative damage on cellular bioenergetics in the ageing skin. In his first postdoctoral role, Jackson worked with Hexis Labs Ltd and Newcastle University in a Knowledge Transfer Partnership associate role, applying scientific experience to improve Hexis Lab Ltd productivity and profitability in their early stage business development. Starting at Bentley University in December 2019, his current research interests focus on trends in new drug discovery including funding of R&D and societal impact of pharmaceutical activity. In addition to his current research, he also holds an adjunct professor role at Bentley University, teaching Human Biology within the department of Natural and Applied Sciences.
Nusrat Rahman, PhD, is a Research Associate at the Center for Integration of Science and Industry at Bentley University. She holds a PhD in Biological sciences from University of Maryland Baltimore County. During her PhD and as a doctoral research fellow at the US Food and Drug Administration and the Maryland Psychiatric Research Center, she has studied biological mechanisms of cancer and psychiatric medications. Prior to joining the Center, she held a research associate position at Bentley University's Health Thoughts Leadership Network where she studied pharmacogenetic and psychosocial contributors to outcomes of addiction treatment. At the Center, she will study the innovation landscape of psychiatric and pain medications, specifically opioids and benzodiazepines. She also teaches comparative healthcare system in Bentley's undergraduate program.
Edward W. Zhou, PharmD, is a Post-Doctoral Fellow at the Center for Integration of Science and Industry at Bentley University. He received his Doctor of Pharmacy degree from Massachusetts College of Pharmacy and Health Sciences, Boston, MA. He obtained a certificate from the MIT xPRO Drug and Medical Device Development Program. During his predoctoral internship, Edward worked with Pfizer Global Regulatory Affairs in organizing internal and public information databases for the pending FDA Oncologic Drugs Advisory Committee review. During his Newton-Wellesley Hospital rotation, Edward created adjustable python code packages for interpreting health outcome metrics from EPIC metadata. He has co-authored several peer-reviewed publications at Brigham and Women's Hospital, Harvard Medical School, which focus on the identification of drug targets and novel pharmacotherapeutics for neurological disorders. Starting at Bentley University in February 2021, his current research projects include the integration of research algorithms into existing database frameworks and the improvement of search field functionality and accuracy to expand the scope of future research projects.
Kevin (Zhihao) Zhang is a Research Assistant at the Center for Integration of Science and Industry at Bentley University. He received his BS in Applied Mathematics from Northeastern University in China and his MS degree in Business Analytics from Bentley. His primary responsibility at the Center is assisting in data analytics components of different projects, such as data cleaning, data visualization, nonlinear curve fitting and database management.
Juliana Harrison is a Program Assistant at the Center for Integration of Science and Industry at Bentley University. She received her BS in Marketing and Liberal Studies (Health and Industry) from Bentley. Her primary responsibilities consist of a variety of administrative, programming, and communications work to ensure smooth operation of the Center. This includes effective coordination and support of the Center’s meetings, events, filing system, publications, website, social media, and external relationships.
Michael Boss, PhD, MBA, is an Executive in Residence at the Center for Integration of Science and Industry at Bentley University. Boss has been a leader in the biotechnology industry for more than 30 years as a scientist and senior executive. As a group leader at Celltech, he was lead inventor of the landmark “Boss patent,” which enabled genetic engineering and manufacture of recombinant, monoclonal antibodies and generated >$1 billion in revenues. Dr. Boss co-founded Oros Instruments, a successful developer of protein purification equipment that was acquired by Biotage. He subsequently joined Genica Pharmaceuticals as Vice President of Research and Development and later Vice President of Operations, where he had a central role in building Genica (renamed Athena Diagnostics) into the leading developer of neurological and genetic tests and the first company to undertake DNA sequencing for human genetic testing. Later Boss held the position of Vice President, Corporate Office of Technology, at Elan Corporation and Chief Operating Officer of Xanthus Pharmaceuticals Inc., leading its acquisition by Antisoma, where he continued in senior executive positions. From 2012 to 2019, Boss led the program at Summit Therapeutics, Inc. as Chief Technology Officer to develop a therapy for Duchenne Muscular Dystrophy. Under his leadership the program progressed from pre-clinical to a proof-of-concept Phase 2 trial. Boss negotiated a license deal with Sarepta Therapeutics Inc. for European and Latin American commercial rights where Summit received $40 million upfront with a total potential deal value of some $941 million in milestone payments. He has a BSc and PhD from London University and an MBA from London Business School, trained in immunology at ICRF London with Dr. Mel Greaves and Dr. Martin Raff and was a post-doctoral fellow with Dr. David Baltimore at the Center for Cancer Research at MIT.
Nancy Hsiung, PhD, is an Executive in Residence at the Center for Integration of Science and Industry at Bentley University. She has more than 30 years of experience in the biotechnology industry, in both scientific and managerial positions as well as in the investment community. For the past 11 years, Hsiung worked with GeneChem Management Inc, a venture fund headquartered in Montreal, where her responsibilities included sourcing, assessing and managing investment opportunities. Prior to GeneChem, Nancy was a consultant whose activities range from strategic planning, business development, technology assessment, market research and financing for biotechnology and biopharmaceutical companies. She started her career on the operational side as a scientist with Integrated Genetics (now part of Genzyme, now Sanofi) where she established the company's gene expression and tissue culture capabilities, as a member of the management team at Applied Biotechnology, whose focus was on vaccines and oncology and as the U.S. head of Corporate Development for Toyobo Corporation's (a large Japanese multinational) biopharmaceutical division. Hsiung received a BA degree from the University of Pennsylvania and a PhD degree in chemistry from Columbia University; she completed her post-doctoral studies in molecular biology at Yale University and Princeton University. She holds more than 15 patents and patent applications worldwide and has written 12 publications/abstracts.
Current Undergraduate Researchers
Sarah Al-Masri, Elizabeth Czarniak, Nishant Nagalia
Current Graduate Researchers